---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001454"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T08:47:01.120373+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Capricor partners with Nippon Shinyaku for CAP-1002 in Japan; $12M upfront, up to $89M milestones

## Summary
- Exclusive Japan commercialization and distribution agreement for CAP-1002 in Duchenne muscular dystrophy.
- Capricor receives $12M upfront plus up to ~$89M in development and sales milestones.
- Capricor also gets a meaningful double-digit percentage of product revenue from Japan sales.
- Capricor retains marketing authorization and clinical development; Nippon Shinyaku handles distribution.
- Follows a similar U.S. deal with Nippon Shinyaku signed in January 2022.

## SEC filing metadata
- accession: 0001558370-23-001454
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/0001558370-23-001454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/capr-20230210x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001454
- JSON: https://secwatch.observer/filing/0001558370-23-001454.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001454.txt

## Key facts
- Material Agreements
  CAPRICOR THERAPEUTICS, INC. entered into Japan Agreement with Nippon Shinyaku, Co., Ltd. valued at upfront payment of $12 million and ... additional development and sales-based milestone payments of (effective 2023-02-10).
  - Action: entry
  - Agreement: supply
  - Counterparty: Nippon Shinyaku, Co., Ltd.
  - Value: upfront payment of $12 million and ... additional development and sales-based milestone payments of
  - Effective: 2023-02-10
  source text: Capricor Therapeutics, Inc. (the “Company” or “Capricor”) entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Agreement”) with Nippon Shinyaku, Co., Ltd., a Japanese corporation, (“Nippon Shinyaku”) effective February 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/0001558370-23-001454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.